A low-androgen environment sustains redox-active sGC states required to restrain castration-resistant prostate cancer growth via elevated cGMP levels
Castration-resistant prostate cancer (CRPC) remains incurable and fatal, creating a dire need for new safe and effective treatment strategies. We recently reported that the soluble guanylyl cyclase (sGC) stimulator, riociguat, cooperates with standard-of-care androgen deprivation (AD) to inhibit castration-resistant tumor burden by oxygenating hypoxic tumor niches and inducing tumor apoptosis. We…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
